Hi All
The relevant text as follows:
From ANNEX 1 WHO briefing sessions.
Item 2 Implications for industry of the WHO Guidelines for the treatment of malaria.
The WHO Guidelines recommend parasitological (microscopy or RDT ) confirmation before treatment, WITH THE ONLY EXCEPTIONS FOR CHILDREN UNDER 5 YEARS OF AGE in areas of high transmission, where treatment in this group should be based on clinical diagnosis, and for suspected SEVERE malaria if parasitilogical conformation is not immediately possible.
a) uncomplicated P.falciparum malaria
b) P.vivax malaria
c) severe P.falciparum malaria
Quinine or an artemisinin derivative (artesunate, artemether or artemoil )by i.v.. or i.m. route are recommended for treatment of severe malaria. This must be followe by a full treatmment course of an effective ACT as soon as patients are able to tolerate oral medication. Artemisinin derivatives administered through the rectal route are recommended only for pre-referral treatment of severe malaria.
The implications for the pharmaceutical industry of the new WHO malaria treatment guidelines are ro reorient production and marketing activities to ensure that:
1) Artemisinin monotherapies are not used for treatment of uncomplicated malaria, whethr in the form of tablets, oral suspensions, supposittories, recto-capsules or vials for parenteral administration.
2)Artemisinin monotherapies in rectal formulations are used only for pre-referral treatment of severe malaria.
3)Artemisinin monotherapies in parenteral formulations are only used for the management of severe malaria.
NOW isn't that fanatastic that ArTiMist ticks all these boxess
Target treatmet for children under 5 years old.
Treatment for severe malaria
Pre-referral treatment.
ArTiMist treatment beats the socks off Quinine (the recommended treatment)
Monotherapies are permitted for pre-referral treatment.
That is why I am so excited about meetings in March.
kippax
Testing continuing with SUD 003 after successful lodging of patent....someone has to do it
- Forums
- ASX - By Stock
- ALA
- excited about monotherapies
excited about monotherapies, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ALA (ASX) to my watchlist
|
|||||
Last
14.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $147.1M |
Open | High | Low | Value | Volume |
14.5¢ | 14.5¢ | 14.0¢ | $82.82K | 582.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 514820 | 14.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
14.5¢ | 431957 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 514820 | 0.140 |
9 | 330868 | 0.135 |
10 | 616104 | 0.130 |
8 | 691879 | 0.125 |
11 | 791339 | 0.120 |
Price($) | Vol. | No. |
---|---|---|
0.145 | 431957 | 7 |
0.150 | 636710 | 6 |
0.155 | 88709 | 3 |
0.160 | 1471739 | 5 |
0.165 | 322812 | 1 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
ALA (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online